An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Acadia Pharmaceuticals (NASDAQ: ACAD) announced that Dr. Srdjan Stankovic will retire as President at year-end but will continue as an advisor. Dr. Stankovic has been pivotal in advancing Acadia, particularly with the approval of NUPLAZID for Parkinson’s disease psychosis and ongoing drug applications for Rett syndrome and schizophrenia. CEO Steve Davis praised his contributions and the company's exciting R&D portfolio. Acadia remains focused on developing solutions for unmet medical needs in neuroscience.
Positive
Dr. Stankovic's leadership contributed significantly to the commercial success of Acadia, particularly with NUPLAZID's approval.
The company is advancing clinical applications for Rett syndrome and schizophrenia, indicating robust R&D efforts.
Negative
None.
- Dr. Stankovic to transition to advisory role at year-end
SAN DIEGO--(BUSINESS WIRE)--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that its President, Srdjan (Serge) Stankovic, M.D., M.S.P.H., who is responsible for R&D, and Medical and Scientific functions, will retire at the end of the year. A search for a successor to Dr. Stankovic is ongoing. Following his retirement, Dr. Stankovic will provide consulting and advisory services for Acadia on a part-time basis.
“I want to thank Serge for his seven years of dedicated service to Acadia and the impact he’s had on the patients we serve that will extend well beyond his tenure with us,” said Steve Davis, Chief Executive Officer. “Serge played an instrumental role in Acadia becoming a commercial stage company with the approval of NUPLAZID® (pimavanserin) for Parkinson’s disease psychosis. Serge led all of Acadia’s clinical and research efforts, including our trofinetide new drug application currently under review for the treatment of Rett syndrome by the FDA, and our ongoing Phase 3 program for pimavanserin for the treatment of the negative symptoms of schizophrenia. Together with everyone at Acadia, I wish Serge all the best in his retirement and very much look forward to continuing to work with him in his new advisory role.”
“It has been an honor to serve as Acadia’s President and to be a part of a dedicated team of professionals so committed to improving the lives and wellbeing of patients in areas of high unmet medical need,” said Dr. Stankovic, President. “As I look ahead to retirement, I am proud to leave the company with a strong outlook for the future, with an exceptional leadership team and a very exciting R&D portfolio. I want to thank my Acadia colleagues, the management team and the Board for their unwavering support and encouragement during my tenure and I’d like to extend special gratitude to our research participants who have been critical to our success. I look forward to following the ongoing success and growth of this great company.”
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.
Media Contact:
Acadia Pharmaceuticals Inc. Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com
Investor Contact:
Acadia Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
Who is Dr. Srdjan Stankovic and what is his role at Acadia Pharmaceuticals?
Dr. Srdjan Stankovic is the President of Acadia Pharmaceuticals, responsible for R&D and will transition to an advisory role at the end of the year.
What significant contributions did Dr. Stankovic make during his tenure at Acadia?
He played a key role in the approval of NUPLAZID for Parkinson's disease psychosis and led ongoing clinical trials for Rett syndrome and schizophrenia.
What are Acadia Pharmaceuticals' current research efforts?
Acadia is focusing on clinical developments for Rett syndrome and treatments for the negative symptoms of schizophrenia.
What is the future outlook for Acadia Pharmaceuticals after Dr. Stankovic's retirement?
Acadia is poised for growth, backed by a strong leadership team and a promising R&D portfolio.